There is still no approved antiviral therapy for adults with RSV infections. As drug developers, we need to prioritize developing new antiviral therapies for immunocompromised patients.
Complex Molecules, Complex Problems
The support of an experienced CDMO is critical to overcoming complexity when working with a highly potent active pharmaceutical ingredient (HPAPI) and when solving solubility challenges.
LIFE SCIENCE LEADER MAGAZINE
Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.